C3 glomerulonephritis

It often starts with overactivity in a part of the immune system called the complement pathway.
This overactivity harms the kidney filters and leads to C3 glomerulonephritis.
Some risks are written in our DNA, passed down through families.
Others are acquired and include antibodies that keep complement switched on, infections, autoimmune disease, or a disorder that makes abnormal immune proteins.
No clear lifestyle risks are proven, but infections and inflammation can act as triggers, which are key risk factors for C3 glomerulonephritis.

Genetic risk factors

For many, C3 glomerulonephritis runs in families due to changes in genes that control a part of the immune system called complement. These inherited risk factors for C3 glomerulonephritis mainly affect the alternative pathway, which can become overactive and deposit C3 in the kidneys. The exact change varies between families, and some people carry a variant without kidney problems. Carrying a genetic change doesn’t guarantee the condition will appear.

• CFH variants: Changes in the complement factor H (CFH) gene can weaken the natural brake on complement, allowing extra C3 activity in the kidney filters. These variants often follow a dominant pattern in families and raise the chance of C3 glomerulonephritis, but severity varies.

• CFHR gene rearrangements: Extra copies, deletions, or hybrid genes in the CFHR1–CFHR5 region can upset how complement is controlled. This structural change is a well-recognized inherited driver of this condition in some families.

• CFHR5 variants: A specific CFHR5 change causes CFHR5 nephropathy, a familial form that often shows the C3 glomerulonephritis pattern on kidney biopsy. It is usually inherited in an autosomal dominant way and is reported most often in families of Cypriot ancestry.

• C3 variants: Some changes in the C3 gene make the complement reaction more active or longer-lasting. These gain-of-function variants can directly lead to C3 buildup in the kidneys seen in C3 glomerulonephritis.

• Factor B variants: Changes in the CFB (factor B) gene can stabilize the enzyme that drives the alternative pathway. This pushes the system toward too much C3 activation and can predispose to disease.

• Factor I variants: Variants in the CFI (factor I) gene reduce a key protein that turns off complement once it has started. Lower control allows ongoing C3 activation and raises genetic risk.

• CD46 variants: Rare changes in the CD46 (also called MCP) gene, a cell-surface controller of complement, have been found in some people with this condition. They seem less common than CFH or CFHR changes but may modify risk and severity.

• Family history: When several relatives are affected, this often reflects a dominant inheritance with variable penetrance. A negative family history does not rule out a genetic cause, because new changes or mild cases can go unrecognized.

• Multiple genetic hits: In some families, more than one complement gene variant is present and the combination increases risk. This helps explain why age at onset and course can differ widely, even within one family.

Transmission

C3 glomerulonephritis is not contagious—you can’t catch it from someone, and you can’t give it to others. It develops when a part of the immune system called complement stays too active and injures the kidney filters; this process is not spread by touch, air, food, water, or sex. Some people develop C3 glomerulonephritis because their immune system makes certain antibodies later in life; these are acquired, not infectious.

In others, changes in genes that control the complement system can run in families, which means close relatives may share a higher chance of the condition. If you’re wondering how C3 glomerulonephritis is inherited, the pattern varies by gene, and a genetics professional can explain personal risks, including the possibility of a new (not inherited) change.

When to test your genes

Consider genetic testing if you were diagnosed with C3 glomerulonephritis at a young age, have recurring disease after transplant, or a strong family history of kidney disease. Testing can uncover complement pathway variants that guide targeted therapy and monitoring. Ask your nephrologist about complement gene panels and how results could personalize your care.

Many people ask, “What does this mean for my future?”, and the answer with C3 glomerulonephritis depends on how active the inflammation is, how quickly it’s treated, and whether complications like high blood pressure or repeated relapses occur. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. Some people have long quiet stretches with stable kidney function, while others see protein in the urine, swelling, and rising creatinine that gradually reduce kidney performance. Early symptoms of C3 glomerulonephritis can be subtle—foamy urine, ankle puffiness, or higher blood pressure—so catching these changes early and adjusting treatment can slow damage.

Looking at the long-term picture can be helpful. About one‑third to one‑half of people with C3 glomerulonephritis progress to advanced chronic kidney disease over 10 years, and a portion will need dialysis or a kidney transplant in their lifetime. Relapses can happen even after a good response, and the condition may come back in a transplanted kidney, though careful monitoring and targeted therapies can lower that risk. Mortality is mostly linked to kidney failure and cardiovascular disease rather than the condition itself, so controlling blood pressure, reducing protein in the urine, and managing cholesterol meaningfully improves survival.

The outlook is not the same for everyone, but newer treatments that target the complement pathway, along with standard care like blood pressure blockers and steroids or other immune therapies when needed, have improved kidney outcomes for many people. Genetic testing can sometimes provide more insight into prognosis. Keep regular appointments—small adjustments can improve long-term health.

Treatment for C3 glomerulonephritis focuses on protecting kidney function, calming the overactive part of the immune system that drives C3 buildup, and managing day-to-day symptoms like swelling and high blood pressure. Doctors often start with blood pressure control (usually with ACE inhibitors or ARBs), diuretics for fluid, and measures to lower protein in the urine; steroids and other immune-suppressing medicines may be added if protein loss or inflammation stays high. In selected cases, targeted drugs that block the complement system (such as C5 or C3 inhibitors) or B‑cell therapies are considered, especially when kidney function is worsening despite standard care. If kidney failure develops, dialysis or a kidney transplant may be needed, though the condition can sometimes recur after transplant. Not every treatment works the same way for every person, so your doctor may adjust your plan over time based on kidney tests, urine protein levels, and how you feel.

Genetic factors can influence how the immune system’s complement pathway behaves in C3 glomerulonephritis. In some families, changes in genes that regulate complement make this system more likely to stay switched on, which can injure the kidney’s filtering units over time. People often ask about the genetic causes of C3 glomerulonephritis, and the answer is that inherited variants and, in others, acquired antibody drivers can both contribute—yet many people have no family history. Having a gene change doesn’t always mean you will develop the condition. When doctors suspect a hereditary component to C3 glomerulonephritis, they may suggest blood tests that measure complement activity and, sometimes, genetic testing to look for changes in complement-related genes; results can clarify risk and guide monitoring but rarely give a simple yes-or-no prediction. Discussing your family history and test options with a genetic counselor can help you make sense of what this means for you and your relatives.

Infections can trigger or worsen kidney inflammation in C3 glomerulonephritis, so flares sometimes follow a chest, throat, or skin infection. Someone might notice their symptoms flare when another condition is active. In older adults, abnormal antibody proteins from a bone‑marrow–related issue (often called a monoclonal gammopathy) can drive or aggravate C3 glomerulonephritis, so doctors may screen for this when kidney findings are hard to explain. C3 glomerulonephritis also shares pathways with atypical hemolytic uremic syndrome, and when these overlap, people may see a sudden drop in kidney function along with blood or platelet changes. Early symptoms of C3 glomerulonephritis—such as swelling, foamy urine, or rising blood pressure—can be harder to control when diabetes, long‑standing high blood pressure, or chronic liver disease are present. Managing these related conditions closely can reduce strain on the kidneys and help keep C3 glomerulonephritis more stable over time.

How genes can cause diseases

Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.

Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.